Related Experiment Video

Updated: May 14, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Antithrombotic therapy in atrial fibrillation: aspirin is rarely the right choice

Ian N Sabir1, Gareth D K Matthews, Christopher L-H Huang

  • 1Physiological Laboratory, University of Cambridge, Downing Street, Cambridge CB2 3EG, UK. ins20@cam.ac.uk

Postgraduate Medical Journal
|February 14, 2013
PubMed

Insights

Warfarin therapy, when well-managed, is more effective than aspirin for preventing stroke in atrial fibrillation patients. Aspirin is rarely the optimal choice for stroke prevention in this population.

Area of Science:

  • Cardiology and Thrombosis
  • Pharmacology and Therapeutics

Background:

  • Atrial fibrillation is a common arrhythmia increasing ischemic stroke risk due to thrombus formation.
  • Novel oral anticoagulants are available, but warfarin and aspirin remain primary therapies.
  • A common misconception is that warfarin carries a higher bleeding risk than aspirin.

Purpose of the Study:

  • To evaluate the comparative effectiveness and safety of warfarin versus aspirin for stroke prevention in atrial fibrillation.
  • To clarify the bleeding risk associated with well-managed warfarin therapy.
  • To provide guidance on appropriate antithrombotic therapy selection based on stroke risk stratification.

Main Methods:

  • Review and analysis of existing data on warfarin, aspirin, and novel oral anticoagulants for atrial fibrillation.
  • Comparison of stroke prevention efficacy and bleeding risks across different antithrombotic agents.
  • Assessment of stroke risk using the CHA2DS2-VASc score.

Main Results:

  • Well-managed warfarin therapy (INR 2-3) has minimal impact on bleeding risk.
  • Warfarin is twice as effective as aspirin in preventing stroke in atrial fibrillation.
  • Patients with atrial fibrillation and a CHA2DS2-VASc score >0 should receive warfarin or a novel oral anticoagulant.

Conclusions:

  • For patients with atrial fibrillation and a stroke risk factor (CHA2DS2-VASc >0), warfarin or a novel oral agent is recommended.
  • Antithrombotic therapy is not recommended for patients at very low risk of stroke.
  • Aspirin is generally not the preferred agent for stroke prevention in atrial fibrillation.

Keywords:
AnticoagulantAntithromboticAspirinAtrial FibrillationWarfarin

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...